Yes, there is a known association between GLP-1 receptor agonists and pancreatitis, and retatrutide carries that same concern
Like exenatide, lixisenatide demonstrates reliable control of blood glucose and provides modest weight loss, typically less than 3 kg depending on the duration of treatment (Sheng et al., 2024)
Frequency: Once per week (subcutaneous)
Lilly has been collaborating with the FDA to resolve supply issues, increase production and implement measures to stabilize the supply chain
'For example, the dose I'm on raises my resting heart rate by two or three beats, which is a big deal for me, but the benefits are great.' Before Johnson was taking a GLP-1, a 2021 Frontiers of Endocrinology study expanded on GLP-1s' efficacy beyond weight loss
If you have questions about your current prescription or are experiencing treatment-related fatigue, discuss your options openly with your healthcare provider